<DOC>
	<DOC>NCT01085812</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of F2695 sustained release (SR) relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).</brief_summary>
	<brief_title>Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week open-label treatment period with F2695 SR are randomized to continue F2695 SR or switch to placebo under double-blind conditions for up to 24 weeks of additional treatment.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Men and women, 1865 years old Currently meet the DSMIVTR criteria for Major Depressive Disorder The patient's current depressive episode must be at least 4 weeks in duration Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control Patients with a history of meeting DSMIVTR criteria for: any manic or hypomanic episode schizophrenia or any other psychotic disorder obsessivecompulsive disorder Patients who are considered a suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>